Avadel Pharmaceuticals plc (AVDL) Financial Statements (2024 and earlier)

Company Profile

Business Address BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN, 15
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments105,11196,499157,22173,19964,15812,675
Cash and cash equivalents31,16773,98150,70871,7229,7749,325
Short-term investments73,94422,518106,5131,47754,3843,350
Receivables12,1036929,09718,9569,86813,629
Inventory, net of allowances, customer advances and progress billings10,380   3,5704,770
Inventory10,380   3,5704,770
Prepaid expense4,3731,5233,1791,0182,1162,145
Other current assets913228271457107225
Other undisclosed current assets1,3222,5242,722169,8242,56191,407
Total current assets:134,202100,843192,490263,45482,380124,851
Noncurrent Assets
Operating lease, right-of-use asset2,5911,7132,6522,604 
Property, plant and equipment5858392853595441,911
Intangible assets, net (including goodwill)16,83616,83616,83616,83619,30420,120
Goodwill16,83616,83616,83616,83618,49118,491
Intangible assets, net (excluding goodwill)     8131,629
Other noncurrent assets10,15211,32233,77724,93939,27436,146
Other undisclosed noncurrent assets3321,2321,2253,4459,9347,272
Total noncurrent assets:30,49631,94254,77548,18369,05665,449
TOTAL ASSETS:164,698132,785247,265311,637151,436190,300
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35,66015,22414,8309,43525,91025,271
Taxes payable   73
Accounts payable11,4337,8907,6792,9346,1003,503
Accrued liabilities24,2277,3347,1516,50119,81021,695
Debt  37,668   106
Other liabilities2611,9415,2705,2003,8753,453
Due to related parties   5,5549,439
Contract with customer, liability114
Other undisclosed current liabilities934960900474645 
Total current liabilities:36,85555,79321,00015,10935,98438,383
Noncurrent Liabilities
Long-term debt and lease obligation  91,614144,104130,050121,686115,734
Long-term debt, excluding current maturities  91,614142,397128,210121,686115,734
Liabilities, other than long-term debt7,3446,5233,9174,21220,64633,403
Due to related parties   11,77319,401
Other liabilities5,6545,7433,9174,2128,87314,002
Operating lease, liability1,6907801,7071,840 
Other undisclosed noncurrent liabilities32,760   2,319 
Total noncurrent liabilities:40,10498,137148,021134,262144,651149,137
Total liabilities:76,959153,930169,021149,371180,635187,520
Equity
Equity, attributable to parent87,739(21,145)78,244162,266(29,199)2,780
Preferred stock 52555  
Common stock898628586583429427
Treasury stock, value     (49,998)(49,998)
Additional paid in capital855,452589,783549,349566,916434,391433,756
Accumulated other comprehensive loss(23,167)(26,341)(23,940)(21,051)(22,806)(23,416)
Accumulated deficit(745,496)(585,220)(447,756)(384,187)(391,215)(357,989)
Total equity:87,739(21,145)78,244162,266(29,199)2,780
TOTAL LIABILITIES AND EQUITY:164,698132,785247,265311,637151,436190,300

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues27,96311611022,33459,215103,269
Sublease income 123116110336 
Cost of revenue(846)(3,345) (6,105)(17,065)(25,151)
Cost of goods and services sold(846)  (5,742)(12,125)(17,516)
Gross profit:27,117(3,229)11016,22942,15078,118
Operating expenses(164,966)(95,216)(85,599)(10,414)(66,262)(183,044)
Other undisclosed operating loss  (116)(57)   
Operating income (loss):(137,849)(98,561)(85,546)5,815(24,112)(104,926)
Nonoperating income (expense)87(536)2,126(1,267)(1,987)2,351
Investment income, nonoperating87(536)2,126(832)(1,609)452
Other nonoperating income (expense)    (435)(378)1,899
Interest and debt expense(23,015)(12,342)(9,942)(12,994)(12,483)(10,622)
Other undisclosed income from continuing operations before equity method investments, income taxes    3,364  
Loss from continuing operations before equity method investments, income taxes:(160,777)(111,439)(93,362)(5,082)(38,582)(113,197)
Other undisclosed income from continuing operations before income taxes   217   
Loss from continuing operations before income taxes:(160,777)(111,439)(93,145)(5,082)(38,582)(113,197)
Income tax expense (benefit)501(26,025)15,81612,1105,35617,893
Income (loss) from continuing operations:(160,276)(137,464)(77,329)7,028(33,226)(95,304)
Income (loss) before gain (loss) on sale of properties:(77,329)7,028(33,226)(95,304)
Net income (loss) available to common stockholders, diluted:(160,276)(137,464)(77,329)7,028(33,226)(95,304)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(160,276)(137,464)(77,329)7,028(33,226)(95,304)
Other comprehensive loss      
Comprehensive income (loss):(160,276)(137,464)(77,329)7,028(33,226)(95,304)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,174(2,401)(2,889)1,755610(150)
Comprehensive income (loss), net of tax, attributable to parent:(157,102)(139,865)(80,218)8,783(32,616)(95,454)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: